Innate Pharma (IPHA) Operating Expenses (2019 - 2024)
Historic Operating Expenses for Innate Pharma (IPHA) over the last 6 years, with Q4 2024 value amounting to -$76.6 million.
- Innate Pharma's Operating Expenses rose 417.63% to -$76.6 million in Q4 2024 from the same period last year, while for Jun 2025 it was -$156.6 million, marking a year-over-year decrease of 9563.87%. This contributed to the annual value of $77.6 million for FY2024, which is 346.23% down from last year.
- According to the latest figures from Q4 2024, Innate Pharma's Operating Expenses is -$76.6 million, which was up 417.63% from -$80.0 million recorded in Q4 2023.
- In the past 5 years, Innate Pharma's Operating Expenses ranged from a high of -$75599.3 in Q4 2022 and a low of -$83.0 million during Q4 2021
- In the last 5 years, Innate Pharma's Operating Expenses had a median value of -$80.0 million in 2023 and averaged -$64.3 million.
- In the last 5 years, Innate Pharma's Operating Expenses soared by 9990.89% in 2022 and then crashed by 10565903.78% in 2023.
- Quarter analysis of 5 years shows Innate Pharma's Operating Expenses stood at -$81.9 million in 2020, then dropped by 1.3% to -$83.0 million in 2021, then surged by 99.91% to -$75599.3 in 2022, then tumbled by 105659.04% to -$80.0 million in 2023, then grew by 4.18% to -$76.6 million in 2024.
- Its Operating Expenses stands at -$76.6 million for Q4 2024, versus -$80.0 million for Q4 2023 and -$75599.3 for Q4 2022.